Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer

BACKGROUND: Trastuzumab has been prevailingly accepted as a beneficial treatment for gastric cancer (GC) by targeting human epidermal growth factor receptor 2 (HER2)-positive. However, the therapeutic resistance of trastuzumab remains a major obstacle, restricting the therapeutic efficacy. Therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Chaoran, Xue, Pei, Zhang, Luyang, Pan, Ruijun, Cai, Zhenhao, He, Zirui, Sun, Jing, Zheng, Minhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106878/
https://www.ncbi.nlm.nih.gov/pubmed/30134903
http://dx.doi.org/10.1186/s12957-018-1475-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106878/
https://www.ncbi.nlm.nih.gov/pubmed/30134903
http://dx.doi.org/10.1186/s12957-018-1475-6

Ejemplares similares